# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lili Boulanger (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET025-SYN-TD
- Date: 1915-04-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odile Marchetti-Rowe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review at week 12, the first maintenance dose of risankizumab. **S**

## History of present illness

Ms. Boulanger had her third infusion at week 8 and starts maintenance today with the 360 mg on-body injector, which she applied herself in clinic after teaching. Prednisone ended five weeks ago without return of symptoms. The norovirus illness two weeks ago settled in three days. She now has one or two formed stools a day and no pain (Harvey-Bradshaw Index 2). Her liver tests at week 8, drawn with the infusion, were normal, and the final mycobacterial culture was negative at six weeks. Her concert went ahead at the end of March. Her periods have returned. She has regained 3.4 kg since diagnosis. **S**

| Element | Detail |
|---|---|
| Interval change | Induction complete; prednisone stopped five weeks ago; norovirus two weeks ago, resolved |
| Activity | Harvey-Bradshaw Index 2 (clinical remission) |
| Week-8 tests | Liver enzymes and bilirubin normal |
| Today | First maintenance dose, self-injected; zoster vaccine dose 2 |
| Work | Concert performed; composing again |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy good |
| Gastrointestinal | Negative | One or two formed stools a day; no pain or blood |
| Genitourinary | Negative | Periods returned |
| Musculoskeletal | Negative | No joint pain |
| Psychiatric | Negative | Mood good |

5 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs **S**
- Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12 **S**
- Cholecalciferol (vitamin D3) 1889 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/68 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 48.4 kg; BMI 18.9 kg/m². All vital signs are synthetic.

Hemoglobin: 12.6 g/dL; MCV: 83 fL; Ferritin: 86 ng/mL; CRP: 3 mg/L; Fecal calprotectin: 210 ug/g (high); Albumin: 4.1 g/dL; ALT: 19 U/L; AST: 21 U/L; Total bilirubin: 0.6 mg/dL; 25-hydroxyvitamin D: 34 ng/mL. All results are synthetic.

## Change since baseline

- Hemoglobin: 10.6 g/dL (low) at baseline, 12.6 g/dL at this visit **S**
- MCV: 76 fL (low) at baseline, 83 fL at this visit **S**
- Ferritin: 9 ng/mL (low) at baseline, 86 ng/mL at this visit **S**
- CRP: 38 mg/L (high) at baseline, 3 mg/L at this visit **S**
- Fecal calprotectin: 1240 ug/g (high) at baseline, 210 ug/g (high) at this visit **S**
- Albumin: 3.3 g/dL (low) at baseline, 4.1 g/dL at this visit **S**
- ALT: 16 U/L at baseline, 19 U/L at this visit **S**
- AST: 19 U/L at baseline, 21 U/L at this visit **S**
- 25-hydroxyvitamin D: 18 ng/mL (low) at baseline, 34 ng/mL at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; BMI 18.9 |
| Eyes | No jaundice |
| Abdomen | Soft, non-tender; no mass |
| Skin | Injection site on the abdomen without reaction |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Crohn disease in steroid-free clinical remission at week 12** (K50.80). Harvey-Bradshaw Index 2 and CRP 3 mg/L, normal. Fecal calprotectin 210 ug/g, down from 1240 but not yet normal: mucosal healing is still in progress, so the target is not yet reached. **S**
   - Risankizumab 360 mg every 8 weeks at home.
   - Calprotectin and CRP again in about three months.
   - Ileocolonoscopy in the autumn to confirm endoscopic response.
2. **Iron deficiency anemia, resolved** (D50.0). Hemoglobin 12.6 g/dL, MCV 83, ferritin 86. **S**
   - Hemoglobin and ferritin every six months while the disease is controlled.
3. **Vitamin D deficiency, resolved** (E55.9). 25-hydroxyvitamin D 34 ng/mL on replacement; calcium stopped with the prednisone. **S**
   - Continue vitamin D3 1889 units daily.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptoms and Harvey-Bradshaw Index | Every visit | Completed today | 2: clinical remission, steroid-free |
| Laboratory | CRP | Every visit | Completed today | 3 mg/L, normal |
| Laboratory | Fecal calprotectin | About three months after starting treatment | Completed today | 210 ug/g, down from 1240; not yet at target |
| Laboratory | Liver enzymes and bilirubin during risankizumab induction | Through at least week 12 | Completed today | ALT 19, AST 21, bilirubin 0.6 today; normal at week 8 with the infusion. Induction monitoring complete; routine checks from now on |
| Laboratory | Hepatitis B antibody after the booster | One to two months after the dose | Completed today | Drawn today, three months after the booster, after the deviation recorded at week 4: anti-HBs 86 mIU/mL, protective. No harm resulted |
| Laboratory | Hemoglobin, MCV, and ferritin | After iron, then every 6 to 12 months | Completed today | Hemoglobin 12.6 g/dL, MCV 83, ferritin 86 |
| Laboratory | Vitamin D | After replacement | Completed today | 34 ng/mL |
| Laboratory | Albumin and weight | Every visit | Completed today | Albumin 4.1 g/dL; weight 48.4 kg |
| Laboratory | Mycobacterial culture of the biopsies | Final result at six to eight weeks | Up to date | Final: no growth at six weeks; intestinal tuberculosis excluded |
| Medication safety | Vaccines on biologic therapy | As scheduled | Completed today | Recombinant zoster dose 2 today; no live vaccines |
| Self-management | Self-injection teaching | At the first maintenance dose | Completed today | On-body injector applied by her under supervision |
| Imaging | Ileocolonoscopy for endoscopic response | Six to twelve months after starting treatment | Due | In the autumn |

## Goal progress

- Reach a diagnosis, with tuberculosis excluded, within two weeks. Outcome by 1915-01-28: Ileocolonoscopy, biopsies, MR enterography, interferon-gamma release assay, and chest X-ray completed in nine days; Crohn disease diagnosed and intestinal tuberculosis made very unlikely, with the mycobacterial culture still pending. **S**
- Steroid-free clinical remission by week 12 to 16 of treatment. Outcome by 1915-04-27: Harvey-Bradshaw Index 2 at week 12, five weeks after the prednisone taper ended. **S**
- Normal CRP and fecal calprotectin by six months, and endoscopic response at six to twelve months. In progress; target 1915-10-05. **S**
- Regain weight to a BMI of 19 or more and correct iron and vitamin D. In progress; target 1915-08-03. **S**
- Perform her March concert and keep composing through treatment. Outcome by 1915-04-27: Composing most mornings; the concert went ahead in late March with a plan for bathroom access. **S**

## Medication changes

- Started: Risankizumab 360 mg in 2.4 mL by subcutaneous on-body injector every 8 weeks (maintenance), from week 12 **S**

## Guideline basis

- ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025), American College of Gastroenterology
- ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025), American College of Gastroenterology
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021), International Organization for the Study of Inflammatory Bowel Diseases
- SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026), U.S. National Library of Medicine, DailyMed

## Follow-up

- Risankizumab every 8 weeks at home. Review in three months with CRP and calprotectin. **S**
- Next scheduled visit 1915-08-03: six-month review on maintenance risankizumab. **S**
